


**Macrophages are recruited to hypoxic tumor areas and acquire a Pro-Angiogenic M2-Polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin**

**Supplemental Information**



**Suppl.1: Comparison Chemotoxic Data for Macrophage Co-Culture Hypoxic Cancer Cells Vs Macrophage/Cancer Cells Co-Culture Subject to Hypoxia**

**Suppl.2: RayBio Human Cytokine Antibody Array (5) MAP**

	1	2	3	4	5	6	7	8
<b>A</b>	GRO- $\alpha$	IL-10	MIP-1 $\beta$	Angiogenin	Eotaxin-3	IGFBP-2	NT-3	Pos
<b>B</b>	GRO	IL-8	MIG	IGF-1	Eotaxin-2	IGFBP-1	NAP-2	Pos
<b>C</b>	GM-CSF	IL-7	MDC	EGF	Eotaxin	HGF	MIP-3 $\alpha$	TIMP-2
<b>D</b>	GCSF	IL-6	MCSF	TNF- $\beta$	Ck $\beta$ 8-1	GDNF	MIF	TIMP-1
<b>E</b>	ENA-78	IL-5	MCP-3	TNF- $\alpha$	BLC	GCP-2	MCP-4	TGF- $\beta$ 3
<b>F</b>	Neg	IL-4	MCP-2	TGF- $\beta$ 1	BDNF	Fractalkine	LIGHT	TGF- $\beta$ 2
<b>G</b>	Neg	IL-3	MCP-1	TARC	Leptin	Flt-3 Ligand	LIF	PIGF
<b>H</b>	Pos	IL-2	IFN- $\gamma$	SDF-1	PDGF-BB	FGF-9	IP-10	PARC
<b>I</b>	Pos	IL-1 $\beta$	IL-15	SCF	VEGF	FGF-7	IL-16	Osteoprotegerin
<b>J</b>	Pos	IL-1 $\alpha$	IL-13	RANTES	Thrombopoietin	FGF-6	IGFBP-4	Osteopontin
<b>K</b>	Pos	I-309	IL-12p40p70	MIP-1 $\delta$	OncostatinM	FGF-4	IGFBP-3	NT-4

No.	MCF-7	MDAMB-231
1.	OncostatinM	OncostatinM
2.	-	RANTES
3.	FGF-6	-
4.	VEGF	VEGF
5.	-	IL-3
6.	-	MCP-1
7.	-	TAR-C
8.	Eotaxin	Eotaxin
9.	TNF- $\beta$	TNF- $\beta$
10.	Eotaxin-2	-
11.	-	MIP-1 $\beta$
12.	IL-10	-
13.	-	Leptin

**Suppl. 3: List of Human Cytokines Upregulated in Hypoxic Tumour Cell Conditioned Media in Comparison to Normoxic Tumour Cell Conditioned Media**

**Correlation between  
HIF-1 $\alpha$  Vs Oncostatin M**

Total no. of field Evaluated: 74

Level of HIF 1- $\alpha$	High:	Low /UD:		
		41	33	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
41	0	2	31	

Chi square test with (yates corrected) Significant  
(p < .001) association between HIF-1 $\alpha$  and Oncostatin M

**Correlation between  
Oncostatin M Vs CD206**

Total no. of field Evaluated: 60

Level of Oncostatin M	High:	Low /UD:		
		33	27	
Level of CD206	High:	Low/UD:	High:	Low/UD:
33	0	1	26	

Chi square test with (yates corrected) Significant  
(p < .001) association between Oncostatin M and CD206

**Correlation between  
HIF-1 $\alpha$  Vs Eotaxin**

Total no. of field Evaluated: 65

Level of HIF 1- $\alpha$	High:	Low /UD:		
		36	29	
Level of Eotaxin	High:	Low/UD:	High:	Low/UD:
36	0	2	27	

Chi square test with (yates corrected) Significant  
(p < .001) association between HIF-1 $\alpha$  and Eotaxin

**Correlation between  
Eotaxin Vs CD206**

Total no. of field Evaluated: 54

Level of Eotaxin	High:	Low /UD:		
		31	23	
Level of CD206	High:	Low/UD:	High:	Low/UD:
29	2	1	22	

Chi square test with (yates corrected) Significant  
(p < .001) association between Eotaxin and CD206

**Numbers represent fields showing presence of indicated antigen evaluated; UD =Undetectable level.**

**Suppl.4: Collective summary of Immunohistochemical Observations of all (14) the Human Breast Cancer Specimen**

**Patient wise correlation between**  
**HIF-1 $\alpha$  Vs Oncostatin M**

Total no. of field Evaluated: 11

Level of HIF 1- $\alpha$	High:		Low /UD:	
	7		4	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
	7	0	0	4
Total no. of field Evaluated:4				

Level of HIF 1- $\alpha$	High:		Low /UD:	
	2		2	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
	2	0	0	2
Total no. of field Evaluated:4				

Level of HIF 1- $\alpha$	High:		Low /UD:	
	4		0	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
	4	0	0	0
Total no. of field Evaluated:5				

Level of HIF 1- $\alpha$	High:		Low /UD:	
	2		3	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
	2	0	0	3
Total no. of field Evaluated:5				

Level of HIF 1- $\alpha$	High:		Low /UD:	
	2		3	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
	2	0	1	2
Total no. of field Evaluated:5				

**Patient wise correlation between**  
**Oncostatin M Vs CD206**

Total no. of field Evaluated: 11

Level of Oncostatin M	High:		Low /UD:	
	7		4	
Level of CD206	High:	Low/UD:	High:	Low/UD:
	7	0	0	4
Total no. of field Evaluated:3				

Level of Oncostatin M	High:		Low /UD:	
	2		1	
Level of CD206	High:	Low/UD:	High:	Low/UD:
	2	0	0	1
Total no. of field Evaluated:5				

Level of Oncostatin M	High:		Low /UD:	
	5		0	
Level of CD206	High:	Low/UD:	High:	Low/UD:
	5	0	0	0
Total no. of field Evaluated:5				

Level of Oncostatin M	High:		Low /UD:	
	3		2	
Level of CD206	High:	Low/UD:	High:	Low/UD:
	3	0	0	2
Total no. of field Evaluated:5				

Level of Oncostatin M	High:		Low /UD:	
	4		1	
Level of CD206	High:	Low/UD:	High:	Low/UD:
	4		0	1
Total no. of field Evaluated:5				

Patient No. 3

Patient No. 25

Patient No. 28

Patient No. 41

Patient No. 42

Total no. of field Evaluated:5

Level of HIF 1- $\alpha$	High:		Low /UD:	
	2		3	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
	2	0	0	3

Total no. of field Evaluated:10

Level of HIF 1- $\alpha$	High:		Low /UD:	
	7		3	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
	7	0	0	3

Total no. of field Evaluated:2

Level of HIF 1- $\alpha$	High:		Low /UD:	
	1		1	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
	1	0	0	1

Total no. of field Evaluated: 10

Level of HIF 1- $\alpha$	High:		Low /UD:	
	6		4	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
	6	0	0	4

Total no. of field Evaluated:2

Level of HIF 1- $\alpha$	High:		Low /UD:	
	1		1	
Level of Oncostatin M	High:	Low/UD:	High:	Low/UD:
	1	0	0	1

Total no. of field Evaluated:4

Level of HIF 1- $\alpha$	High:		Low /UD:	
	3		1	

Total no. of field Evaluated:4

Level of Oncostatin M	High:		Low /UD:	
	1		3	
Level of CD206	High:	Low/UD:	High:	Low/UD:
	1	0	0	3

Total no. of field Evaluated:3

Level of Oncostatin M	High:		Low /UD:	
	1		2	
Level of CD206	High:	Low/UD:	High:	Low/UD:
	1	0	1	1

Total no. of field Evaluated:3

Level of Oncostatin M	High:		Low /UD:	
	1		2	
Level of CD206	High:	Low/UD:	High:	Low/UD:
	1	0	0	2

Total no. of field Evaluated: 3

Level of Oncostatin M	High:		Low /UD:	
	2		1	
Level of CD206	High:	Low/UD:	High:	Low/UD:
	2	0	0	1

Total no. of field Evaluated:2

Level of Oncostatin M	High:		Low /UD:	
	1		1	
Level of CD206	High:	Low/UD:	High:	Low/UD:
	1	0	0	1

Total no. of field Evaluated:5

Level of Oncostatin M	High:		Low /UD:	
	2		3	

<b>Patient No. 57</b>	<b>Level of Oncostatin M</b>	High: 3	Low/UD: 0	High: 0	Low/UD: 1	<b>Level of CD206</b>	High: 2	Low/UD: 0	High: 0	Low/UD: 3
	Total no. of field Evaluated:6									
<b>Patient No. 59</b>	<b>Level of HIF 1-<math>\alpha</math></b>	High: 3		Low /UD:			<b>Level of Oncostatin M</b>	High: 2		Low /UD: 4
	Total no. of field Evaluated:3									
<b>Patient No. 60</b>	<b>Level of Oncostatin M</b>	High: 3	Low/UD: 0	High: 1	Low/UD: 2	<b>Level of CD206</b>	High: 2	Low/UD: 0	High: 0	Low/UD: 4
	Total no. of field Evaluated:3									
<b>Patient No. 59</b>	<b>Level of HIF 1-<math>\alpha</math></b>	High: 1	Low /UD:	2		<b>Level of CD206</b>	High: 2	Low/UD: 0	High: 0	Low/UD: 1
	Total no. of field Evaluated:3									
<b>Patient No. 60</b>	<b>Level of Oncostatin M</b>	High: 0	Low/UD: 0	High: 0	Low/UD: 2	<b>Level of CD206</b>	High: 0	Low/UD: 0	High: 0	Low/UD: 2
	Total no. of field Evaluated:2									

### Patient wise correlation between HIF-1 $\alpha$ Vs Eotaxin

<b>Patient No. 3</b>	<b>Level of HIF 1-<math>\alpha</math></b>	High: 4		Low /UD:			<b>Level of Eotaxin</b>	High: 2		
	Total no. of field Evaluated:6									
<b>Patient No. 25</b>	<b>Level of Eotaxin</b>	High: 4	Low/UD: 0	High: 0	Low/UD: 2	<b>Level of CD206</b>	High: 2	Low/UD: 0	High: 0	Low/UD: 1
	Total no. of field Evaluated:5									
<b>Patient No. 25</b>	<b>Level of HIF 1-<math>\alpha</math></b>	High: 3		Low /UD:			<b>Level of Eotaxin</b>	High: 2		Low /UD: 2
	Total no. of field Evaluated:5									

### Patient wise correlation between Eotaxin Vs CD206

<b>Patient No. 3</b>	<b>Level of Eotaxin</b>	High: 2			Low /UD:			<b>Level of CD206</b>	High: 2	
	Total no. of field Evaluated: 3									
<b>Patient No. 25</b>	<b>Level of CD206</b>	High: 2	Low/UD: 0	High: 0	Low/UD: 1	<b>Level of Eotaxin</b>	High: 2		Low /UD:	
	Total no. of field Evaluated:4									
<b>Patient No. 25</b>	<b>Level of HIF 1-<math>\alpha</math></b>	High: 3		Low /UD:			<b>Level of Eotaxin</b>	High: 2		Low /UD: 2
	Total no. of field Evaluated:5									



<b>Patient No. 51</b>	<b>Level of HIF 1-<math>\alpha</math></b>	<b>High:</b>	<b>Low /UD:</b>		<b>Level of Eotaxin</b>	<b>High:</b>	<b>Low /UD:</b>	
		2	2			2	1	
<b>Patient No. 52</b>	<b>Level of Eotaxin</b>	<b>High:</b>	<b>Low/UD:</b>	<b>High:</b>	<b>Low/UD:</b>	<b>Level of CD206</b>	<b>High:</b>	<b>Low/UD:</b>
		2	0	1	1		2	0
	Total no. of field Evaluated:	5				Total no. of field Evaluated:	5	
<b>Patient No. 53</b>	<b>Level of HIF 1-<math>\alpha</math></b>	<b>High:</b>	<b>Low /UD:</b>		<b>Level of Eotaxin</b>	<b>High:</b>	<b>Low /UD:</b>	
		3	2			3	2	
<b>Patient No. 54</b>	<b>Level of Eotaxin</b>	<b>High:</b>	<b>Low/UD:</b>	<b>High:</b>	<b>Low/UD:</b>	<b>Level of CD206</b>	<b>High:</b>	<b>Low/UD:</b>
		3	0	0	2		3	0
	Total no. of field Evaluated:	4				Total no. of field Evaluated:	5	
<b>Patient No. 55</b>	<b>Level of HIF 1-<math>\alpha</math></b>	<b>High:</b>	<b>Low /UD:</b>		<b>Level of Eotaxin</b>	<b>High:</b>	<b>Low /UD:</b>	
		1	3			2	3	
<b>Patient No. 56</b>	<b>Level of Eotaxin</b>	<b>High:</b>	<b>Low/UD:</b>	<b>High:</b>	<b>Low/UD:</b>	<b>Level of CD206</b>	<b>High:</b>	<b>Low/UD:</b>
		1	0	0	3		2	0
	Total no. of field Evaluated:	4				Total no. of field Evaluated:	3	
<b>Patient No. 57</b>	<b>Level of HIF 1-<math>\alpha</math></b>	<b>High:</b>	<b>Low /UD:</b>		<b>Level of Eotaxin</b>	<b>High:</b>	<b>Low /UD:</b>	
		3	1			2	1	
<b>Patient No. 58</b>	<b>Level of Eotaxin</b>	<b>High:</b>	<b>Low/UD:</b>	<b>High:</b>	<b>Low/UD:</b>	<b>Level of CD206</b>	<b>High:</b>	<b>Low/UD:</b>
		3	0	0	1		2	0
	Total no. of field Evaluated:	5				Total no. of field Evaluated:	4	
<b>Patient No. 59</b>	<b>Level of HIF 1-<math>\alpha</math></b>	<b>High:</b>	<b>Low /UD:</b>		<b>Level of Eotaxin</b>	<b>High:</b>	<b>Low /UD:</b>	
		2	3			2	2	
<b>Patient No. 60</b>	<b>Level of Eotaxin</b>	<b>High:</b>	<b>Low/UD:</b>	<b>High:</b>	<b>Low/UD:</b>	<b>Level of CD206</b>	<b>High:</b>	<b>Low/UD:</b>
		2	0	1	1		2	0
	Total no. of field Evaluated:	5				Total no. of field Evaluated:	4	

Patient No. 60

2	0	0	3
---	---	---	---

Total no. of field Evaluated:3

Level of HIF 1- $\alpha$	High:	Low /UD:	
	2	1	
Level of Eotaxin	High:	Low/UD:	High:
	2	0	0
			1

Patient No. 60


2	0	0	2
---	---	---	---

Total no. of field Evaluated:4

Level of Eotaxin	High:	Low /UD:	
	2	2	
Level of CD206	High:	Low/UD:	High:
	2	0	0
			2


**Numbers represent fields showing presence of indicated antigen evaluated; UD =Undetectable level.**

**Suppl. 5: Summary of Immunohistochemical Observations of Individual Human Breast Cancer Specimen**



Each bar represents the mean intensity of five different fields.


#### Suppl.6: Quantification of Oncostatin M/Eotaxin and CD206 Expression (Fluorescence intensity) in Hypoxic (HIF-1 $\alpha$ Positive) area of Human Breast Cancer Specimen



Each bar represents the mean intensity of five different fields.

**Suppl.7: Quantification of CD31Expression (Florescence intensity) in 4T1/BALB/c Tumour Tissue**

(A) Mc-l-1 (B) CD16 Expression



**Suppl. 8: Real-Time Quantitative PCR of Macrophage Specific Markers in THP-1 Derived Macrophages**